Corcept trades GR-II antagonist royalties for non-dilutive cash from Pharmakon
This article was originally published in Scrip
Executive Summary
Corcept Therapeutics has sold a total of $45 million worth of royalties for the recently launched Cushing's syndrome drug Korlym (mifepristone 300mg tablets) and any of its next-generation drugs in the same GR-II antagonist class to Pharmakon Advisors for $30 million.